waynakyo
Experienced Member
- Reaction score
- 464
Never heard of this before. Anyone knows smth?
pubmed.ncbi.nlm.nih.gov
Materials and methods: This was a single-center retrospective study involving 140 consecutive adults with confirmed Androgenetic Alopecia, who received a single session of ACM (Regenera Activa®). Efficacy was evaluated 1-6 months after treatment, by analyzing the change of trichometry parameters, which were assessed using TrichoScan digital image analysis.
Results: Depending on the scalp region, there was increase in mean hair density by 4.5-7.12 hair/cm2, average hair thickness by 0.96-1.88 μm, % thick hair by 1.74-3.26%, and mean number of follicular units by 1.30-2.77, resulting in an increase of cumulative hair thickness by 0.48-0.56 unit. Additionally, the frontal region showed a significant decrease in % thin hair (-1.81%, p = 0.037) and yellow dots (-1.93 N/cm2, p = 0.003). A favorable response was observed in 66.4% of the participants in the frontal region. Further, a gender-specific effect of treatment was observed.
Conclusion: ACM is a promising treatment in Androgenetic Alopecia with a short-term favorable response observed in up to approximately two-thirds of patients.
Keywords: androgenetic alopecia; autologous cellular micrografts; efficacy; pattern hair loss; regrowth.
Short-Term Efficacy of Autologous Cellular Micrografts in Male and Female Androgenetic Alopecia: A Retrospective Cohort Study - PubMed
ACM is a promising treatment in Androgenetic Alopecia with a short-term favorable response observed in up to approximately two-thirds of patients.
pubmed.ncbi.nlm.nih.gov
Abstract
Purpose: Autologous cellular micrografts (ACM) is a novel treatment method in hair loss, and few data are available regarding its efficacy. The present study was carried out to assess the short-term clinical efficacy of a single application of ACM in the treatment of male and female androgenetic alopecia (Androgenetic Alopecia).Materials and methods: This was a single-center retrospective study involving 140 consecutive adults with confirmed Androgenetic Alopecia, who received a single session of ACM (Regenera Activa®). Efficacy was evaluated 1-6 months after treatment, by analyzing the change of trichometry parameters, which were assessed using TrichoScan digital image analysis.
Results: Depending on the scalp region, there was increase in mean hair density by 4.5-7.12 hair/cm2, average hair thickness by 0.96-1.88 μm, % thick hair by 1.74-3.26%, and mean number of follicular units by 1.30-2.77, resulting in an increase of cumulative hair thickness by 0.48-0.56 unit. Additionally, the frontal region showed a significant decrease in % thin hair (-1.81%, p = 0.037) and yellow dots (-1.93 N/cm2, p = 0.003). A favorable response was observed in 66.4% of the participants in the frontal region. Further, a gender-specific effect of treatment was observed.
Conclusion: ACM is a promising treatment in Androgenetic Alopecia with a short-term favorable response observed in up to approximately two-thirds of patients.
Keywords: androgenetic alopecia; autologous cellular micrografts; efficacy; pattern hair loss; regrowth.